Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Efficacy of ATG-201 in Adult Participants With Autoimmune Diseases

NCT07732309 is registered in ClinicalTrials.gov with Antengene Biologics Limited as lead sponsor.

NCT NCT07732309
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07732309 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Efficacy of ATG-201 in Adult Participants With Autoimmune Diseases
Lead sponsor
Antengene Biologics Limited
Phase
Phase 1
Overall status
Not yet recruiting
Start date
September 1, 2026
Completion date
June 1, 2029
Enrollment
149 (estimated)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

autoimmune diseases, sjogren's disease, systemic lupus erythematosus, systemic sclerosis (ssc)